Enliven Therapeutics, Inc. Profile Avatar - Palmy Investing

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being …

Biotechnology
US, Boulder [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Enliven Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Enliven Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Enliven Therapeutics, Inc..

End of ELVN's Analysis
CIK: 1672619 CUSIP: 29337E102 ISIN: US29337E1029 LEI: - UEI: -
Secondary Listings
ELVN has no secondary listings inside our databases.